Background -Homocysteine is known to be an independent risk factor for congenital heart
Introduction
Congenital heart disease (CHD) is one of the most common birth defects and is the leading cause of infant death worldwide with an incidence of 19 to 75 per 1,000 live births. 1 The etiology of CHD is quite complex and involves both environmental and genetic factors, such as environmental exposure, maternal lifestyle, and genetic susceptibility of both the parents and the fetus. 2 Clinical research over the past half-century suggests that maternal periconceptional administration of folic acid can reduce the occurrence of congenital abnormities, including a 40-60% decrease in CHD. [3] [4] [5] [6] [7] [8] [9] Folate acts as a one-carbon donor, which is involved in both the synthesis of nucleotides and in methyl transfer reactions that are important for the methylation of DNA, proteins, and lipids. 3, [10] [11] [12] However, the precise role of folate during cardiac morphogenesis remains unclear.
Extensive genetic analyses of folate-related genes have been undertaken due to the ability of maternal periconceptional folic acid supplementation to protect from CHD. Polymorphic variants of genes in the folate and homocysteine pathways have been associated with increased risk of CHD, including a common variant (c.677 C>T) of the MTHFR gene (5, 10-methylene tetrahydrofolate reductase). However, the studies analyzing the association between the MTHFR polymorphism and CHD have yielded controversial results. [13] [14] [15] [16] [17] [18] Increased maternal homocysteine levels were also found to be associated with an increased risk of CHD in the offspring. 19, 20 The remethylation of homocysteine to form methionine is catalyzed by methionine synthase (MTR).
Methionine synthase reductase (MTRR, EC 2.1.1.135) is required for the activation of methionine synthase. Therefore, MTRR activity is essential for the adequate remethylation of homocysteine.
It has been reported that although the common MTRR c.66 A>G (p.I22M) missense mutation is not significantly associated with CHD in children, the homozygotes mutant G allele is associated with elevated plasma homocysteine concentrations in pregnant women. 21 However, to date there have not been any published studies on the possible correlation between variations in the non-coding region of MTRR and CHD. In the current study, we have investigated polymorphisms in the non-coding region of the MTRR gene in three independent
case-control studies with 2,340 CHD patients and 2,270 controls from the Han Chinese population. We identified a variant, c.56+781 A>C in the intron-1 of MTRR, that reduces the expression of MTRR and increases the plasma homocysteine level. Moreover, this functional c.56+781 A>C variant is significantly associated with an increased risk of stratified CHD manifestations in all three case-control pairs and in the combined dataset.
Materials and Methods

Study subjects
We analyzed samples from three independent case-control groups. The Shanghai group consisted of 602 congenital heart disease patients and 660 healthy controls. The plasma homocysteine concentration was measured in 522 healthy undergraduate student volunteers from Fudan University.
All study protocols were reviewed and approved by the local medical Ethics Committee, and written consent was obtained from the parents and/or patients prior to the commencement.
SNP identification and genotyping
Genomic DNA was isolated from the venous blood using conventional regents. The MTRR promoter and non-coding regions were amplified by PCR from the -1648 to +994 region (chr5:
7867716-7870217, NC_000005.9, GI: 224589817) in 32 unrelated individuals randomly selected from both the Shanghai and Shandong groups for variant screening by sequencing. Direct dye terminator sequencing of the PCR products was carried out using the ABI Prism BigDye system according to the manufacturer's instructions (ABI, Foster City, CA, USA). Selected SNPs were genotyped using SNaPshot analysis (ABI). The samples for sequencing and genotyping were run on an ABI 3730 automated sequencer and analyzed by SeqMan and Peakscan, respectively. All of the primer pair DNA sequences are listed in Supplemental Table 2 .
Plasmid constructs, host cell culture and luciferase assays
To construct the MTRR reporter plasmid, we amplified the 2915-bp fragment from -1917 to +998 of MTRR ( Figure 1A) , which contains the A allele of SNP c.56+781 A>C, by PCR from genomic DNA. The primers utilized are presented in Supplemental After another 24 hours of culture, the transfected cells were lysed in 0.5 ml lysis buffer (Promega), incubated on ice for 10 minutes and centrifuged at 6,000 r.p.m. for 3 minutes. Forty microliters of the supernatant were then assayed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega). Three independent transfection experiments were performed, and each luciferase assay was carried out in triplicate.
Surface plasmon resonance (SPR) analysis
SPR analysis was carried out using the ProteOn XPR36 Protein Interaction Array System 
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were conducted using the EZ ChIP Kit (Upstate, Lake Placid, NY, USA). Table 2 .
Statistical analysis
Differences in demographic features and allelic or genotypic frequencies between the CHD cases and controls were compared using the 2 test. Hardy-Weinberg equilibrium was also tested using the 2 test in the controls. To evaluate the associations between the genotypes and the CHD risk, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression analysis with adjustments for age and sex. Other differences were evaluated using the Student's t test. All statistical tests were two-tailed, with P <0.05 set as the significance level, and were performed using SPSS 15.0 software (SPSS, Chicago, IL, USA).
Results
MTRR noncoding variant c.56+781 A>C significantly increases the risk of CHD
We identified 5 common polymorphisms within the screened regulatory region of the MTRR gene with minor allele frequency (MAF) >0.1, including rs2966952, rs326118, rs72716536, rs326119 and rs12653464 ( Figure 1A ).
In the first-stage association study, we genotyped all 5 SNPs in 265 CHD cases versus 253 controls in the Shanghai group. We found that the allele and genotype distribution of only one SNP (rs326119, c.56+781 A>C) was statistically different between the CHD and control subjects.
The minor allele C at rs326119 was associated with increased risk of congenital heart disease (Supplemental Table 3 ). Similar results were also obtained in the validation study, which compared 254 cases with 300 controls in the Shandong group (Supplemental Table 3 ). The variant c.56+781 A>C in the first intron of MTRR ( Figure 1A) has not been reported to be associated with any disease so far. To further validate this association, we performed a second-stage association study by expanding the sample size to 602 cases and 660 controls in the compared to the wild-type. However, we did not observe any association between the reported MTRR c.66 A>G variant and CHD risk in any of the three Han Chinese groups or in the combined study (Supplemental Table 4 ).
All genotype frequencies were in accordance with the Hardy-Weinberg expectation among the control subjects (P>0.05).
MTRR c.56+781 A>C is highly related to septation defects
A stratified analysis of c.56+781 A>C was performed according to the standard CHD classifications. 22 Figure 1B) .
Although the MTRR mRNA levels in the hearts after birth may not be the same as the embryonic levels, the difference in MTRR transcriptional levels between individuals bearing different alleles are reflected.
To further demonstrate that the decrease in MTRR mRNA levels is caused by the functional c.56+781 A>C variant, we performed in vitro luciferase assays. As expected, a plasmid containing the mutant C allele displayed significantly lower luciferase expression than the wild type A allele, manifesting a 39% reduction in human embryonic kidney 293 (HEK293) cells and a 48% reduction in rat cardiac myocyte (H9C2) cells ( Figure 1C ). This result was consistent with the real-time quantitative PCR results, which confirmed our hypothesis that the noncoding c.56+781 A>C variant did functionally influence the transcription of MTRR.
The c.56+781 C variant attenuates transcription factor affinity
To test the binding capacity of transcription factors to the different c.56+781 A/C alleles, we carried out SPR analysis. In the direct SPR assay using HEK293 nuclear extraction, we observed that the SPR-binding activity of the A-allele was more than 1,000-fold higher than that of C-allele ( Figure 2A) . Next, we performed SPR competition assays by adding non-biotinylated A/C oligonucleotides as competitors at 5-to 10-fold excess. The SPR responses in both competition assays confirmed the direct assay results, indicating that the A-allele oligonucleotides have a higher affinity to certain transcription factors than the C-allele ( Figure 2B ). Because the minor allele C has low binding affinity and reduced transcriptional levels, it is possible that MTRR is transcribed only in the presence of a bound transcriptional activator, reduced binding of which can account for the decreased transcriptional activity. The computational analysis (Alibaba2 software) indicated that the A>C alteration destroyed a binding site for CEBP , which is a bZIP transcription factor ( Figure 2C ).
The finding that the binding affinity of CEBP was attenuated by the c.56+781 C allele probe was further confirmed using ChIP assays. The CEBP antibody precipitated lysates from HEK293 cells and two cardiac tissue samples, and the resulting MTRR PCR product indicated that the MTRR c.56+781 position was occupied by CEBP in vivo ( Figure 3A) . The quantification by SNaPshot assay showed that the MTRR c.56+781 A allele had a higher affinity, up to 1.83 to 2.16-fold, for binding CEBP than the C allele ( Figure 3B ).
c.56+781 A>C influences the human plasma homocysteine concentration
MTRR activity is essential for adequate remethylation of homocysteine, and elevated plasma homocysteine has been considered an independent risk factor for cardiovascular disease. Thus, we hypothesized that the reduced transcriptional activity of MTRR caused by the c.56+781 A>C variant may lead to a deficiency in homocysteine remethylation, which would subsequently raise the plasma homocysteine levels. To test this hypothesis, we quantified the homocysteine levels in 522 healthy undergraduate students using the Axis Homocysteine Enzyme Immunoassay (EIA) assay (Axis-Shield, Norton, MA, USA) and surveyed the correlation between c.56+781 A>C and plasma homocysteine levels. This analysis revealed that the CC genotype was significantly associated with increased plasma homocysteine levels compared to the wild-type AA genotype (Figure 4) . Our findings indicated that this intronic SNP could reduce MTRR expression through the regulation of transcriptional activity, resulting in the accumulation of plasma homocysteine.
Discussion
Epidemiological evidence indicates that periconceptional administration of folic acid leads to a 40-60% reduction in the risk of delivering newborns with CHD, which makes exploring the association between genetic variants in genes involved in folate metabolism and the risk of CHD an attractive pursuit. [3] [4] [5] 10, 11, 24 However, previous efforts on several folate-related gene variants have yielded conflicting or negative results. [13] [14] [15] [16] [17] [18] 25, 26 For example, in the case of the most extensively studied MTHFR c.677 C>T variant, the data published so far do not provide strong evidence for an overall significant association with the CHD risk, either in mothers or in their CHD offspring. Limited studies have been conducted on variants of the MTRR gene. It has been concluded that the extensively studied missense mutation c.66 A>G of MTRR gene has no association with an increased risk of CHD but is associated with elevated plasma homocysteine.
Notably, these studies mainly focused on variations in the coding region, but variations in the noncoding region have been largely ignored. This is therefore the first study to explore non-coding region variants of the MTRR gene and CHD. In this study we identified a functional variant in the first intron of MTRR, c.56+781 A>C, and showed that this noncoding variant significantly increases the CHD risk in a large-scale case-control study in the Han Chinese population. Furthermore, we also demonstrated that the common MTRR c.66 A>G variant was not associated with CHD in our study subjects, confirming previous reports. 25 These results accentuate the potentially important involvement of non-coding region variants of folate pathway core genes in the etiology of CHD. However, further confirmatory studies are needed in other ethnic groups because our initial observations only involved Chinese populations.
We further investigated the mechanism by which the nucleotide substitution in the c.56+781
A>C variant at the first intron of the MTRR gene can affect cardiac development. Not only the detection of in vivo MTRR mRNA levels but also in vitro luciferase assays showed that the minor C allele significantly decreased MTRR transcriptional activity. SPR analysis demonstrated that the major A allele had a higher binding affinity for nucleus proteins compared to the minor C allele. ChIP assays confirmed that the transcription factor CEBP could specifically bind to the MTRR c.56+781 region, and the A allele had a higher affinity than the C allele. Although our results based on in vivo and in vitro experiments suggest that the genetic MTRR c.56+781 A>C variant is strongly associated with increased CHD risk, the important roles played by gene-polymorphism interactions in folate metabolism and cardiac development can be explored later using comprehensive data collected in the same population or even the same samples.
Our results suggest that maintenance of an adequate amount of MTRR mRNA is crucial for cardiac development. Evidence from MTRR hypomorphic mice model strongly supports this hypothesis. Elmore et al. constructed MTRR gene-trap mice with reduced levels of wild-type MTRR mRNA, which prevents the embryo lethality of the MTRR null mice. 27, 28 A quarter of the offspring embryos from MTRR gt/gt mother developed VSD, and 1/3 were affected by VSD. 23 Consistent with this MTRR dosage sensitivity experiment, in our study the c.56+781 A>C variant, which regulates MTRR gene transcription, is strongly correlated with the amount of MTRR and associated with septation defects (1,652 cases, P=6.36×10 -11 ) and VSD (1,220 cases,
P=2.65×10
-8 ) with a high degree of significance.
Because the patients with inherited syndromes accompanied by defective MTRR and the MTRR gt/gt mice are both characterized by elevated plasma levels of total homocysteine, 23, 27, [29] [30] [31] [32] [33] we also analyzed the correlation between the MTRR genotype and plasma homocysteine levels in 522 healthy individuals. We observed significantly increased plasma homocysteine levels in mutant CC genotype carriers compared to wild-type AA genotype carriers. It is known that insufficient MTR/MTRR activity in homocysteine removal in adults can be compensated for by betaine-homocysteine methyltransferase (BHMT) or by cystathionine -synthase (CBS).
However, in the fetus, BHMT is not expressed until day 32 of embryonic development 34, 35 , and
CBS is present at a low level compared with in adults 36, 37 . Therefore, at early stages of embryonic development, especially during the stage between days 15 and 32, which is a critical phase of heart development, embryonic homocysteine is almost exclusively removed by the activity of the dominantly expressed MTR/MTRR pathway. It was reasonably speculated that the relationship between the targeted MTRR genotype and homocysteine concentration correlates more closely at the embryonic stage than in adults.
It has been shown in animal studies that exposure to homocysteine during the critical period of cardiac development increases the incidence of congenital heart disease, especially septation defects. In three studies, the toxic effects of homocysteine on chick embryos were reported with the prevalence of cardiovascular disease ranging from 28% to 82%. [38] [39] [40] One mouse study using in vivo ultrasound examination showed 55% valve regurgitation accompanied with cardiac valve defects after homocysteine exposure, and another mouse study also detected 23% of surviving embryos with ventral septal defects. 38, 41 To obtain additional evidence of the role of homocysteine, we found that noncoding variants in the MTR gene for homocysteine removal are also significantly associated with increased risk of congenital heart disease in the same case-control cohort (unpublished data). Thus MTRR and MTR loci both for homocysteine removal are associated with human hyperhomocysteinemia and congenital heart disease.
Our results strongly suggest that embryos with the MTRR c.56+781 CC genotype are much more fragile than normal and are extremely sensitive to the maternal nutrition supply, especially to having sufficient methionine and 5-methyltetrahydrofolate (5-Me-THF). A fetus with genetic susceptibility to deficient MTRR is prone to suffer from serious hypo-methionine and hyper-homocysteine, which would inevitably result in a greater risk of congenital heart disease if the susceptible fetus is challenged by the absence of maternal folate during the embryonic heart development period.
It is also possible that reduced MTRR dosage would lead to a 5-Me-THF trap and otherwise cause functional folate deficiency, thus influencing de novo thymidylate and purine biosynthesis, which is vital to rapidly proliferating cells during embryogenesis.
In conclusion, our findings demonstrate a significant association between the MTRR c.56+781
A>C variant and an increased risk of congenital heart disease in three independent Han Chinese populations. Because the activity of MTRR is so vital for guaranteeing that the embryo has adequate functional folate during the critical heart development stage, the precondition genetic *Genotype frequencies in case and control participants were compared using 2 test with 2 degrees of freedom (df). **Adjusted for age, sex. ***P value for Hardy-Weinberg equilibrium test in the control subjects. 
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